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:   dried blood spot
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:   dried blood spot
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:   hepatitis B virus

HCV

:   hepatitis C virus

MSM

:   men who have sex with men

OST

:   opioid substitution therapy

PLHIV

:   people living with HIV

PWID

:   people who inject drugs

RCT

:   randomized controlled trial

SIGN

:   Scottish Intercollegiate Guidelines Network

STI

:   sexually transmitted infection

1. INTRODUCTION {#jvh13182-sec-0001}
===============

Across the European Union/European Economic Area (EU/EEA), an estimated 4.7 million people are chronically infected with hepatitis B virus (HBV) and 3.9 million are chronically infected with hepatitis C virus (HCV).[1](#jvh13182-bib-0001){ref-type="ref"} HBV and HCV can both cause acute and chronic hepatitis, potentially leading to the development of cirrhosis, liver cancer or death of infected patients.[2](#jvh13182-bib-0002){ref-type="ref"}, [3](#jvh13182-bib-0003){ref-type="ref"} Early disease and development of liver damage are often asymptomatic,[4](#jvh13182-bib-0004){ref-type="ref"}, [5](#jvh13182-bib-0005){ref-type="ref"}, [6](#jvh13182-bib-0006){ref-type="ref"} meaning that HBV and HCV infection may go undetected for many years[7](#jvh13182-bib-0007){ref-type="ref"} and many infected people remain undiagnosed.[8](#jvh13182-bib-0008){ref-type="ref"}

Transmission of HBV and HCV can occur sexually, through blood‐to‐blood contact or vertically (mother‐to‐child). Over the past decades, there have been shifts in the patterns of transmission in Europe, due to various factors, including improvements in blood transfusion and healthcare safety standards, HBV vaccination programmes, harm reduction programmes targeting injecting drug use, as well as significant changes in patterns of injecting drug use and immigration. However, a number of population groups are still potentially at high risk or have a high burden of HBV/HCV in EU/EEA countries, including people who inject drugs (PWID), men who have sex with men (MSM), people living with HIV (PLHIV), people in prison and migrants from countries of high endemicity.[9](#jvh13182-bib-0009){ref-type="ref"}, [10](#jvh13182-bib-0010){ref-type="ref"}, [11](#jvh13182-bib-0011){ref-type="ref"}

As highly effective treatment options have become available for HBV and HCV,[12](#jvh13182-bib-0012){ref-type="ref"}, [13](#jvh13182-bib-0013){ref-type="ref"} it is crucial that an informed public health response is in place tailored to the local epidemiological situation, which will ensure that those infected are diagnosed and linked to care. Estimates of the undiagnosed fraction in the general population in EU/EEA countries range from 40% to 85% for HBV and 20% to 91% for HCV, with large variability between countries.[11](#jvh13182-bib-0011){ref-type="ref"} The WHO has formulated an action plan to eliminate viral hepatitis as a public health threat in the European region by 2030, setting targets of 50% of people with chronic infection diagnosed by 2020 and 90% by 2030.[14](#jvh13182-bib-0014){ref-type="ref"} To this end, testing programmes must be scaled up in order to reduce the undiagnosed fraction.

Testing can occur through a number of methods and in various settings, depending on the population group targeted and the local epidemiology and healthcare infrastructure. Testing in health care may take place across a range of different settings in primary health care and hospitals as well as other healthcare settings such as sexually transmitted infection (STI) clinics, antenatal services and pharmacies. Outside of formal healthcare facilities, settings within the community, such as homeless shelters, migrant services and community‐based drugs services can offer testing services which are adapted, targeted and made accessible to the populations that frequent them.[15](#jvh13182-bib-0015){ref-type="ref"} Outreach testing, for example using mobile units, street outreach by community health workers, or satellite services based at other agencies can be used to reach people who are not in contact with other health services.[16](#jvh13182-bib-0016){ref-type="ref"} Common testing strategies for hepatitis B and C include universal screening, birth cohort testing or testing targeted towards those at increased risk. In recent years, new technologies such as self‐testing kits, and strategies for testing implementation have been developed, which may be considered for incorporation in countries\' national testing policies and programmes. Evidence around the effectiveness of different interventions in relation to uptake and positivity rates could help inform countries in deciding which strategic approaches to incorporate in national testing programmes.

A systematic review covering HBV and HCV testing studies in key populations in the European region until June 2013 found that, although a large number of studies on testing existed, these were unevenly distributed across Europe and that large gaps existed in certain key populations including migrants, people in prison and MSM.[17](#jvh13182-bib-0017){ref-type="ref"} Previous systematic reviews on testing interventions focused solely on either HBV or HCV,[18](#jvh13182-bib-0018){ref-type="ref"}, [19](#jvh13182-bib-0019){ref-type="ref"}, [20](#jvh13182-bib-0020){ref-type="ref"}, [21](#jvh13182-bib-0021){ref-type="ref"}, [22](#jvh13182-bib-0022){ref-type="ref"}, [23](#jvh13182-bib-0023){ref-type="ref"} specific key populations or settings,[19](#jvh13182-bib-0019){ref-type="ref"}, [21](#jvh13182-bib-0021){ref-type="ref"}, [22](#jvh13182-bib-0022){ref-type="ref"}, [24](#jvh13182-bib-0024){ref-type="ref"} targeted testing interventions[18](#jvh13182-bib-0018){ref-type="ref"}, [23](#jvh13182-bib-0023){ref-type="ref"} or included comparative studies only.[25](#jvh13182-bib-0025){ref-type="ref"} Finally, a comprehensive report on hepatitis testing policies and activities in EU/EEA countries revealed substantial gaps in testing coverage and testing offers targeting specifically higher risk groups across the region.[8](#jvh13182-bib-0008){ref-type="ref"}

The scope of this study was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings. A systematic review was performed to collect, synthesize and analyse available data on HBV/HCV testing outcomes and acceptability measures from EU/EEA countries. This study was conducted as part of a larger project to develop an integrated European testing guidance for HBV, HCV and HIV, coordinated by the European Centre for Disease Prevention and Control (ECDC).

2. METHODS {#jvh13182-sec-0002}
==========

2.1. Search strategy and selection criteria {#jvh13182-sec-0003}
-------------------------------------------

Original research articles were retrieved from PubMed and EMBASE databases on 1 September 2017. PICO questions (Patient/problem, Intervention, Comparison and Outcome[26](#jvh13182-bib-0026){ref-type="ref"}) were formulated (listed in [Supporting information](#jvh13182-sup-0001){ref-type="supplementary-material"}). Search strategies combined controlled (MeSH/Emtree terms) and natural vocabulary on terms for HBV and HCV with terms for intervention and testing and geographic terms (EU/EEA) (detailed in [Supporting Information](#jvh13182-sup-0001){ref-type="supplementary-material"}). The search strategy employed also included terms for linkage to care, however, for the purposes of this article, methods and results applying to approaches to improve testing coverage are presented only. Only studies published between 1 January 2008 and 1 September 2017 were included in the search. Articles in all EU/EEA languages were included.

Only articles reporting data from EU/EEA countries were included. Publications were included which described approaches to improve coverage of testing and reported any of the following outcomes of interest: offer of test, uptake and coverage of testing, positivity rate, acceptability and feasibility outcomes. Studies on unlinked anonymous testing to determine prevalence and studies describing the sensitivity/specificity of laboratory tests were excluded. The full inclusion and exclusion criteria are listed in Table [S3](#jvh13182-sup-0001){ref-type="supplementary-material"}. Only original research articles (ie not reviews) and conference abstracts were included in this review; however, the reference lists of relevant systematic reviews retrieved in the literature search were checked manually for additional original articles not captured by the literature search. Conference abstracts from the International Liver Congress or retrieved in the systematic literature search, reporting relevant quantitative data and published since 2015, were included as grey literature. Additional publications captured were subject to the same inclusion and exclusion criteria listed above.

Two reviewers reviewed titles and abstracts of retrieved publications. Initially, a random sample of 5% was screened in duplicate; the results were then compared and used to refine the inclusion and exclusion criteria. Further rounds of duplicate review were conducted until a level of concordance of more than 95% was achieved, after which the remaining publications were divided between reviewers and screening continued in EndNote. The full texts of selected articles were subsequently screened by two reviewers, of which a random sample of 20% was screened in duplicate and these reached more than 95% concordance. The remaining 80% of publications were divided between the reviewers and screened. Articles were included in case of uncertainty about inclusion or exclusion if this was not resolved after discussion between the reviewers.

2.2. Definitions {#jvh13182-sec-0004}
----------------

Primary health care was defined as health care provided by general practitioners (GPs). Hospital settings included all hospital departments including inpatients, outpatients, medical admissions units and infectious disease units. Other healthcare settings included any formal healthcare settings outside of primary health care or hospital departments, for example STI clinics, pharmacies and prisons. Community‐based testing was defined as any programme or service offering HBV/HCV testing outside of formal health facilities. Drugs services were defined as services offering prevention, support, detox and treatment for addiction to drugs or alcohol, either embedded in healthcare settings or set in the community. Outreach activities were defined as testing activities taking place in the community without a fixed‐site facility, including mobile units or vans, street outreach by community health workers and regular satellite services based at other agencies.

Testing offer rate was defined as the proportion of people targeted by a testing programme who were offered testing, while testing coverage was defined as the percentage of people targeted by a testing programme that received testing. Positivity rate was defined as the percentage of people testing positive for HBsAg and anti‐HCV for HBV and HCV, respectively. When other markers were reported instead, these data were extracted, and the marker was specified in tables.

2.3. Data extraction and quality assessment {#jvh13182-sec-0005}
-------------------------------------------

Relevant data were extracted from included articles and recorded in a data extraction file in Microsoft Excel. A predefined set of variables covering study characteristics, study population details and outcomes was extracted per study. The complete list of variables is provided in Table [S5](#jvh13182-sup-0001){ref-type="supplementary-material"}. The unit for data extraction was study, not article. A study is defined as a report of data on a testing approach or linkage to care approach for HBV or HCV, in a defined country, over a discrete period of time. Therefore, one article may contain more than one study. If a study was captured by two different articles, the study was extracted once and the article with the most detail used as a reference.

The quality of included peer‐reviewed literature was assessed using checklists developed by the Scottish Intercollegiate Guidelines Network (SIGN)[27](#jvh13182-bib-0027){ref-type="ref"} that include the most important criteria on publication quality from the PRISMA and STROBE guidelines. Using these checklists, an overall quality score was assigned per study: high (++), acceptable (+) and low (−). As some of the included publications concerned study designs for which no checklists exist, a list (provided in Table [S6](#jvh13182-sup-0001){ref-type="supplementary-material"}) was compiled of relevant aspects from standard checklists, regarding the level of detail and clarity of the study, appropriateness of study population, data collection and denominator, and the representativeness of the sample, which were answered with yes or no per study. Using the checklist, it was not possible to calculate an overall quality score for these studies; therefore, all relevant articles were included regardless of their quality, but the results of the assessment were taken into consideration in interpreting the results. Articles were excluded, however, when the methods and/or results provided an insufficient level of details making it not possible to accurately extract data. No quality assessment was performed on included grey literature publications.

A set of detailed summary tables were developed per setting (provided in Tables [S7‐S11](#jvh13182-sup-0001){ref-type="supplementary-material"}), containing the following information: study reference, country, study period, study design, study population and specific setting, sample size, outcomes (test offer, coverage and positivity rate, acceptance rate and patient and provider indicators of acceptability and feasibility), critical appraisal and comments. Within each table, findings are ordered by virus, study population, country and year of publication.

3. RESULTS {#jvh13182-sec-0006}
==========

The literature search retrieved 8331 unique publications, of which 370 were selected based on title and abstract and were assessed in full text for eligibility. Of these, 62 articles were retrieved that formed the evidence base for the effectiveness of testing initiatives and interventions (Figure [1](#jvh13182-fig-0001){ref-type="fig"}). Reasons for exclusion of publications are listed in Table [S4](#jvh13182-sup-0001){ref-type="supplementary-material"}. The included publications comprised 93 studies in total, each detailing an intervention designed to improve coverage of HBV or HCV testing in a certain setting. A total of 78 studies were from peer‐reviewed publications and 15 concerned conference abstracts. A formal quality assessment was performed for 19 peer‐reviewed studies; the remainder had study designs which precluded this. Detailed information of each included study is provided in Tables [S7‐S11](#jvh13182-sup-0001){ref-type="supplementary-material"}.

![PRISMA flow diagram for the systematic review](JVH-26-1431-g001){#jvh13182-fig-0001}

3.1. Testing initiatives in primary healthcare settings {#jvh13182-sec-0007}
-------------------------------------------------------

Nine studies that reported outcomes on testing initiatives performed in primary healthcare settings were retrieved[28](#jvh13182-bib-0028){ref-type="ref"}, [29](#jvh13182-bib-0029){ref-type="ref"}, [30](#jvh13182-bib-0030){ref-type="ref"}, [31](#jvh13182-bib-0031){ref-type="ref"}, [32](#jvh13182-bib-0032){ref-type="ref"}, [33](#jvh13182-bib-0033){ref-type="ref"}, [34](#jvh13182-bib-0034){ref-type="ref"}, [35](#jvh13182-bib-0035){ref-type="ref"}, [36](#jvh13182-bib-0036){ref-type="ref"} (Table [1](#jvh13182-tbl-0001){ref-type="table"}). HBV/HCV test offer rates, coverage and positivity rates, where reported, ranged widely between studies. The highest offer rate and coverage reported was 70% and 100%, respectively, in a study targeting migrants.[30](#jvh13182-bib-0030){ref-type="ref"} Very high positivity rates for HCV were reported in initiatives targeting PWID (70%) and homeless people (26%).[29](#jvh13182-bib-0029){ref-type="ref"}, [33](#jvh13182-bib-0033){ref-type="ref"} Two initiatives targeting migrants reported HBV and HCV positivity rates of 0%.[30](#jvh13182-bib-0030){ref-type="ref"}, [32](#jvh13182-bib-0032){ref-type="ref"}

###### 

Evidence base for the effectiveness of testing initiatives in primary healthcare settings

+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Intervention                                                                                                                                                                        | Studies included                                                                                | Target population                                                                  | Test offer                                                                                                                                                | Coverage/number of tests/tested[b](#jvh13182-note-0003){ref-type="fn"}                                                           |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     | Quality of evidence                                                                             |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+=====================================================================================================================================================================================+=================================================================================================+====================================================================================+===========================================================================================================================================================+==================================================================================================================================+
| Risk group testing                                                                                                                                                                  | **HBV**                                                                                         |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 3 studies[30](#jvh13182-bib-0030){ref-type="ref"}, [32](#jvh13182-bib-0032){ref-type="ref"}, [36](#jvh13182-bib-0036){ref-type="ref"}                                           | Migrants (n = 3) (sample size: 47‐560[a](#jvh13182-note-0002){ref-type="fn"})                   | 100%                                                                               | Number tested/tests: 2223                                                                                                                                 | 0%‐6.7%                                                                                                                          |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            |                                                                                                 |                                                                                    | Coverage: 2.3% and 70%                                                                                                                                    |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 3 studies NA                                                                                                                                                                        |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                             |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 4 studies[29](#jvh13182-bib-0029){ref-type="ref"}, [30](#jvh13182-bib-0030){ref-type="ref"}, [32](#jvh13182-bib-0032){ref-type="ref"}, [33](#jvh13182-bib-0033){ref-type="ref"} | PWID (n = 1) (sample size: intervention 485, control NR)                                        | 52% intervention                                                                   | Coverage: 24.8% intervention, 0.3% control                                                                                                                | Comparative study: 70% intervention, 22% control                                                                                 |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 1 study low                                                                                                                                                                         |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 3 studies NA                                                                                                                                                                        |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Homeless (n = 1) (sample size: NR)                                                                                                                                                  |                                                                                                 | Number tested/tests: 460                                                           | 26%                                                                                                                                                       |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    | 9.6% newly diagnosed                                                                                                                                      |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Migrants (n = 2) (sample size: 47 and 560)                                                                                                                                          | 100%                                                                                            | Coverage: 2.3% and 70%                                                             | 0%                                                                                                                                                        |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Birth cohort testing                                                                                                                                                                | **HCV**                                                                                         |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 1 study[28](#jvh13182-bib-0028){ref-type="ref"}                                                                                                                                 | 30‐ to 54‐year‐olds (n = 1) (sample size: Intervention 584, control NR)                         | Comparative study: 72% intervention; 0% control                                    | Comparative study: coverage: 20% intervention; 0% control                                                                                                 | Comparative study: 13% intervention; NA control                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Acceptable                                                                                                                                                                          |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Novel testing                                                                                                                                                                       | **HCV**                                                                                         |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 2 studies[33](#jvh13182-bib-0033){ref-type="ref"}, [35](#jvh13182-bib-0035){ref-type="ref"}                                                                                     | General pop (n = 1) (sample size: 600‐29 600)                                                   |                                                                                    | Coverage (oral): 9.1%‐22%                                                                                                                                 | 0.4%‐4.5%                                                                                                                        |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 2 studies NA                                                                                                                                                                        |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Homeless (n = 1) (sample size: NR)                                                                                                                                                  |                                                                                                 | Number tested/tests (oral): 460                                                    | 26%                                                                                                                                                       |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    | 9.6% newly diagnosed                                                                                                                                      |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Education                                                                                                                                                                           | **HBV**                                                                                         |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 1 study[30](#jvh13182-bib-0030){ref-type="ref"}                                                                                                                                 | Targeted at GPs                                                                                 | 100%                                                                               | Coverage: 70%                                                                                                                                             | 0%                                                                                                                               |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            | Migrants (n = 1) (sample size: 47)                                                              |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| NA                                                                                                                                                                                  |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                             |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 2 studies[30](#jvh13182-bib-0030){ref-type="ref"}, [31](#jvh13182-bib-0031){ref-type="ref"}                                                                                     | Targeted at GPs                                                                                 | 100%                                                                               | Coverage: 70%                                                                                                                                             | 0%                                                                                                                               |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            | Migrants (n = 1); general pop. (n = 1) (sample size: 47[a](#jvh13182-note-0002){ref-type="fn"}) |                                                                                    | Comparative study: number tested: campaign + education (intervention): 57 tests before; 172 during; campaign (control): 86 tests before; 118 during       | Comparative study: campaign + education (intervention): 0% before; 1.7% during; campaign (control): 1.7% before; 0.8% during     |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 1 study low                                                                                                                                                                         |                                                                                                 |                                                                                    | OR of the increase intervention vs control: 2.2 (95% CI 1.5‐3.3)                                                                                          |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 1 study NA                                                                                                                                                                          |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Campaign                                                                                                                                                                            | **HCV**                                                                                         |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| N = 2 studies [31](#jvh13182-bib-0031){ref-type="ref"}, [34](#jvh13182-bib-0034){ref-type="ref"}                                                                                    | Targeted at public                                                                              |                                                                                    | Comparative study: number tested/tests: campaign + education (intervention): 57 tests before; 172 during; campaign (control): 86 tests before; 118 during | Comparative study HCV: campaign + education (intervention): 0% before; 1.7% during; campaign (control): 1.7% before; 0.8% during |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| Quality:                                                                                                                                                                            | General pop. (n = 1) (no sample)                                                                |                                                                                    | OR of the increase intervention vs control: 2.2 (95% CI 1.5‐3.3)                                                                                          |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 1 study low                                                                                                                                                                         |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| 1 study NA                                                                                                                                                                          |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+
| Targeted at GPs/risk groups                                                                                                                                                         |                                                                                                 | Comparative study: number HCV tested/tests: before 5421 tests; during 10 117 tests | Comparative study HCV: before 9.6%; during 6.8%                                                                                                           |                                                                                                                                  |
|                                                                                                                                                                                     |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
| General pop. (n = 1) (no sample)                                                                                                                                                    |                                                                                                 |                                                                                    |                                                                                                                                                           |                                                                                                                                  |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+

Abbreviations: HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; NA: not applicable; NR: not reported; oral: oral sampling; PWID: people who inject drugs; TB: tuberculosis

Denominator not reported for all studies.

Number of tests is only reported here if no data on coverage are available.
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One comparative study on HCV risk group testing in PWID reported testing coverage of 24.8% among PWID in GP practices exposed to the intervention, compared to 0.3% of PWID tested in comparable control practices.[29](#jvh13182-bib-0029){ref-type="ref"} In a comparative study on birth cohort testing for HCV testing in an area of high prevalence of HCV and intravenous drug use, 72% of 30‐ to 54‐year‐olds were offered testing, compared to 0% in a control practice in the same area where birth cohort testing was not implemented.[28](#jvh13182-bib-0028){ref-type="ref"} In an additional comparative study, the number of tests performed increased from 5421 before to 10 117 during a national testing programme which involved awareness‐raising activities for GPs and those at higher risk.[34](#jvh13182-bib-0034){ref-type="ref"} Another comparative study found a significant increase in the number tested when a public awareness campaign was combined with additional educational brochures and training for GPs, which resulted in three times more people being tested, compared to a control group in which only the campaign was implemented and testing rates increased by 1.4 times.[31](#jvh13182-bib-0031){ref-type="ref"}

Two studies provided data on the acceptability and feasibility of testing in primary healthcare settings. Testing acceptance rates were 56% among PWID[29](#jvh13182-bib-0029){ref-type="ref"} and 70% among migrants.[30](#jvh13182-bib-0030){ref-type="ref"} Among PWID interviewed about a testing intervention, all responded positively about the acceptability of provider‐initiated HCV testing. Staff viewed the intervention as an opportunity to facilitate identification and subsequent referral.[29](#jvh13182-bib-0029){ref-type="ref"}

3.2. Testing initiatives in hospital settings {#jvh13182-sec-0008}
---------------------------------------------

Twelve studies were identified on the effectiveness of testing initiatives and interventions in hospital settings[34](#jvh13182-bib-0034){ref-type="ref"}, [35](#jvh13182-bib-0035){ref-type="ref"}, [37](#jvh13182-bib-0037){ref-type="ref"}, [38](#jvh13182-bib-0038){ref-type="ref"}, [39](#jvh13182-bib-0039){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"}, [41](#jvh13182-bib-0041){ref-type="ref"} (Table [2](#jvh13182-tbl-0002){ref-type="table"}). Test offer rates, coverage and HBV/HCV positivity rates varied with high offer rates (83% and 100%) in testing initiatives targeted at migrants and psychiatric patients.[37](#jvh13182-bib-0037){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"}, [41](#jvh13182-bib-0041){ref-type="ref"} Coverage was highest (88.4%) in a study reporting on a universal testing initiative conducted at a single emergency department.[38](#jvh13182-bib-0038){ref-type="ref"} A separate universal testing initiative conducted in multiple emergency departments, however, yielded a much lower overall coverage of 27%, although with variations among testing sites.[39](#jvh13182-bib-0039){ref-type="ref"} Positivity rates for HBV and HCV were higher in studies reporting on initiatives targeted at key populations (2.2%‐7.8% for HBV and 0.3%‐8.7% for HCV) than those aimed at the general population.[37](#jvh13182-bib-0037){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"}, [41](#jvh13182-bib-0041){ref-type="ref"}

###### 

Evidence base for the effectiveness of testing initiatives in hospital settings

+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Intervention                                                                                                                              | Studies included                                            | Setting; target population                            | Test offer                                  | Coverage/number of tests/tested[a](#jvh13182-note-0006){ref-type="fn"} |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
|                                                                                                                                           | Quality of evidence                                         |                                                       |                                             |                                                                        |
+===========================================================================================================================================+=============================================================+=======================================================+=============================================+========================================================================+
| Risk group testing                                                                                                                        | **HBV**                                                     |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 3 studies[37](#jvh13182-bib-0037){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"}, [41](#jvh13182-bib-0041){ref-type="ref"} | Other hospital departments (n = 3) (sample size: 105‐3226)  | Migrants: 100%                                        | Coverage migrants: 28.7% and 61%            | Migrants: 2.2% and 7.8%                                                |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | Migrants (n = 2); psychiatric patients (n = 1)              | Psychiatric patients: 83%                             | Coverage psychiatric patients: 54%          | Psychiatric patients: 7.0%                                             |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| 3 studies NA                                                                                                                              |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                   |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 3 studies[37](#jvh13182-bib-0037){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"}, [41](#jvh13182-bib-0041){ref-type="ref"} | Other hospital departments (n = 3) (sample size: 105‐3226)  | Migrants: 100%                                        | Coverage migrants: 28.7% and 61%            | Migrants: 0.3% and 3.6%                                                |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | Migrants (n = 2); psychiatric patients (n = 1)              | Psychiatric patients: 83%                             | Coverage psychiatric patients: 54%          | Psychiatric patients: 8.7%                                             |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| 3 studies NA                                                                                                                              |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Universal testing                                                                                                                         | **HBV**                                                     |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 2 studies[38](#jvh13182-bib-0038){ref-type="ref"}, [39](#jvh13182-bib-0039){ref-type="ref"}                                           | ED only (n = 2) (sample size: 7807 and 10 000)              |                                                       | Coverage: 27% and 88.4%                     | 0.5% and 0.7%                                                          |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | General population (n = 2)                                  |                                                       |                                             | 0.2% and 0.5% newly diagnosed                                          |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| 2 studies NA                                                                                                                              |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                   |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 2 studies[38](#jvh13182-bib-0038){ref-type="ref"}, [39](#jvh13182-bib-0039){ref-type="ref"}                                           | ED only (n = 2) (sample size: 7807 and 10 000)              |                                                       | Coverage: 27% and 88.4%                     | 1.8% and 5%                                                            |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | General population (n = 2)                                  |                                                       |                                             | 0.6% and 0.7% newly diagnosed                                          |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| 2 studies NA                                                                                                                              |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Novel testing                                                                                                                             | **HCV**                                                     |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[35](#jvh13182-bib-0035){ref-type="ref"}                                                                                       | Other hospital departments (n = 1 (sample size: 600‐29 600) |                                                       | Comparative study: coverage (oral):         | Comparative study:                                                     |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | General population (n = 1)                                  |                                                       | 9.1% (2011)                                 | 0.5% (2011)                                                            |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| NA                                                                                                                                        |                                                             |                                                       | 14% (2012)                                  | 0.5% (2011)                                                            |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
|                                                                                                                                           |                                                             |                                                       | 16.9% (2013)                                | 0.4% (2013)                                                            |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
|                                                                                                                                           |                                                             |                                                       | 22% (2014)                                  | 4.5% (2014)                                                            |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Education                                                                                                                                 | **HBV**                                                     |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[40](#jvh13182-bib-0040){ref-type="ref"}                                                                                       | Targeted at migrants                                        | 100%                                                  | Coverage: 28.7%                             | 2.2%                                                                   |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | Migrants (n = 1) (sample size: 3226)                        |                                                       |                                             |                                                                        |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| NA                                                                                                                                        |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                   |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[40](#jvh13182-bib-0040){ref-type="ref"}                                                                                       | Targeted at migrants                                        | 100%                                                  | Coverage: 28.7%                             | 0.3%                                                                   |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | Migrants (n = 1) (sample size: 3226)                        |                                                       |                                             |                                                                        |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| NA                                                                                                                                        |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Campaign                                                                                                                                  | **HBV**                                                     |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 2 studies[39](#jvh13182-bib-0039){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"}                                           | Targeted at patients                                        |                                                       | Coverage: 27%                               | 0.7%                                                                   |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | General pop. (n = 1) (sample size: 7807)                    |                                                       |                                             | 0.5% newly diagnosed                                                   |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| 3 studies NA                                                                                                                              |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Targeted at‐risk groups                                                                                                                   | 100%                                                        | Coverage: 28.7%                                       | 2.2%                                        |                                                                        |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Migrants (n = 1) (sample size: 3226)                                                                                                      |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                   |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| N = 3 studies[34](#jvh13182-bib-0034){ref-type="ref"}, [39](#jvh13182-bib-0039){ref-type="ref"}, [40](#jvh13182-bib-0040){ref-type="ref"} | Targeted at patients                                        |                                                       | Coverage: 27%                               | 1.8%                                                                   |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Quality:                                                                                                                                  | General pop. (n = 1) (sample size: 7807)                    |                                                       |                                             | 0.7% newly diagnosed                                                   |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| 3 studies NA                                                                                                                              |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+
| Targeted at‐risk groups                                                                                                                   | 100%                                                        | Comparative study: before 10 536 tests; during 12 170 | Comparative study: 9.9% before; 7.9% during |                                                                        |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| General pop. (n = 1) (sample size: NR)                                                                                                    |                                                             | Coverage: 28.7%                                       | 0.3%                                        |                                                                        |
|                                                                                                                                           |                                                             |                                                       |                                             |                                                                        |
| Migrants (n = 1) (sample size: 3226)                                                                                                      |                                                             |                                                       |                                             |                                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------+-------------------------------------------------------+---------------------------------------------+------------------------------------------------------------------------+

Abbreviations: ED, emergency department; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NA, not applicable; NR, not reported; oral, oral sampling.

Number of tests is only reported here if no data on coverage are available.
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One comparative study reported on implementation of oral sampling for HCV testing between 2011 and 2014.[35](#jvh13182-bib-0035){ref-type="ref"} Over this period, coverage increased from 9.1% to 22% and positivity rates increased from 0.5% to 4.5%. In another comparative study, a national programme involving awareness‐raising activities was associated with an increase in number of tests taken in hospitals from 10 536 tests before and 12 170 during the intervention.[34](#jvh13182-bib-0034){ref-type="ref"}

3.3. Testing initiatives in other healthcare settings {#jvh13182-sec-0009}
-----------------------------------------------------

Thirty‐one studies were included relating to other healthcare settings[34](#jvh13182-bib-0034){ref-type="ref"}, [35](#jvh13182-bib-0035){ref-type="ref"}, [42](#jvh13182-bib-0042){ref-type="ref"}, [43](#jvh13182-bib-0043){ref-type="ref"}, [44](#jvh13182-bib-0044){ref-type="ref"}, [45](#jvh13182-bib-0045){ref-type="ref"}, [46](#jvh13182-bib-0046){ref-type="ref"}, [47](#jvh13182-bib-0047){ref-type="ref"}, [48](#jvh13182-bib-0048){ref-type="ref"}, [49](#jvh13182-bib-0049){ref-type="ref"}, [50](#jvh13182-bib-0050){ref-type="ref"}, [51](#jvh13182-bib-0051){ref-type="ref"}, [52](#jvh13182-bib-0052){ref-type="ref"}, [53](#jvh13182-bib-0053){ref-type="ref"}, [54](#jvh13182-bib-0054){ref-type="ref"}, [55](#jvh13182-bib-0055){ref-type="ref"}, [56](#jvh13182-bib-0056){ref-type="ref"}, [57](#jvh13182-bib-0057){ref-type="ref"}, [58](#jvh13182-bib-0058){ref-type="ref"}, [59](#jvh13182-bib-0059){ref-type="ref"}, [60](#jvh13182-bib-0060){ref-type="ref"}, [61](#jvh13182-bib-0061){ref-type="ref"}, [62](#jvh13182-bib-0062){ref-type="ref"}, [63](#jvh13182-bib-0063){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"} (Table [3](#jvh13182-tbl-0003){ref-type="table"}), which included antenatal services, clinics for people with no health insurance, drug services (embedded in health services), migrant clinics, pharmacies, prisons, public health clinics and STI clinics. Testing coverage during or after interventions were found to vary widely between and within settings, with the highest coverage levels reported by studies in Italian migrant clinics (87%‐91.4%),[48](#jvh13182-bib-0048){ref-type="ref"}, [54](#jvh13182-bib-0054){ref-type="ref"} clinics for people with no health insurance (71%‐98.2%)[44](#jvh13182-bib-0044){ref-type="ref"}, [57](#jvh13182-bib-0057){ref-type="ref"} and public health clinics (90% and 98%).[51](#jvh13182-bib-0051){ref-type="ref"} Four studies on novel testing initiatives yielded high coverage levels when dried blood spot (DBS) sampling or rapid tests were used (up to 98.2% for rapid testing and up to 96.6% for DBS).[44](#jvh13182-bib-0044){ref-type="ref"}, [50](#jvh13182-bib-0050){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"} The highest positivity rates for both diseases were reported in studies targeting drug users or PWID (up to 48% anti‐HBc positive for HBV and up to 61% for HCV).[43](#jvh13182-bib-0043){ref-type="ref"}, [51](#jvh13182-bib-0051){ref-type="ref"}, [52](#jvh13182-bib-0052){ref-type="ref"}, [59](#jvh13182-bib-0059){ref-type="ref"}, [62](#jvh13182-bib-0062){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"} No studies conducted in other healthcare settings reported test offer rates.

###### 

Evidence base for the effectiveness of testing initiatives in other health care settings

+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Studies included                                                                                                      | Setting/target population                                                                               | Coverage/number of tests/tested[c](#jvh13182-note-0010){ref-type="fn"} |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Quality of evidence                                                                                                   |                                                                                                         |                                                                        |
+====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+=======================================================================================================================+=========================================================================================================+========================================================================+
| Risk group testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | **HBV**                                                                                                               |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 6 studies[48](#jvh13182-bib-0048){ref-type="ref"}, [54](#jvh13182-bib-0054){ref-type="ref"}, [56](#jvh13182-bib-0056){ref-type="ref"}, [57](#jvh13182-bib-0057){ref-type="ref"}, [61](#jvh13182-bib-0061){ref-type="ref"}, [62](#jvh13182-bib-0062){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                            | Migrant clinic (n = 2) (sample size: 516 and 4078)                                                                    | Coverage: 87% and 91.4%                                                                                 | 6.0% and 7.7%                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 6 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Prisons (n = 2) (sample size: 3468[a](#jvh13182-note-0008){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Number tested: 160                                                                                                    | 0% and 4.4%                                                                                             |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Coverage: 65.3%                                                                                                       | 1.5% newly diagnosed                                                                                    |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Drug services (n = 1) (sample size: 287 and 2024)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Coverage: 34% and 69%                                                                                                 | 33% and 48% (anti‐HBc)                                                                                  |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Clinic for people with no health insurance (n = 1) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Coverage: 90% when screening is proposed during a prevention interview; 71% without interview                         | 6.9%                                                                                                    |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 15 studies[43](#jvh13182-bib-0043){ref-type="ref"}, [45](#jvh13182-bib-0045){ref-type="ref"}, [47](#jvh13182-bib-0047){ref-type="ref"}, [48](#jvh13182-bib-0048){ref-type="ref"}, [49](#jvh13182-bib-0049){ref-type="ref"}, [51](#jvh13182-bib-0051){ref-type="ref"}, [52](#jvh13182-bib-0052){ref-type="ref"}, [56](#jvh13182-bib-0056){ref-type="ref"}, [57](#jvh13182-bib-0057){ref-type="ref"}, [58](#jvh13182-bib-0058){ref-type="ref"}, [59](#jvh13182-bib-0059){ref-type="ref"}, [61](#jvh13182-bib-0061){ref-type="ref"}, [62](#jvh13182-bib-0062){ref-type="ref"}, [63](#jvh13182-bib-0063){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"} | STI clinics (n = 1) (sample size: 3365)                                                                               | Coverage: 69%                                                                                           | 0.65%                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | MSM (n = 1)                                                                                                           |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 3 studies acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 1 study low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 11 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Prisons (n = 3) (sample size: 3468 ‐ 3600[a](#jvh13182-note-0008){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Number tested: 160                                                                                                    | 22.8% and 33.8%                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Coverage: 64.6%                                                                                                       | 1.5% newly diagnosed                                                                                    |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparative study (DBS): ORs for effect of the intervention on testing rate: OR: 0.86; 95% CI: 0.71‐1.06; *P* = 0.153 |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Drug services (n = 3) (sample size: 287‐2566)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Coverage: 53%‐84.2%                                                                                                   | 26%‐61%                                                                                                 |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Antenatal services (n = 1) (sample size: 4369)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28.3% received targeted screening                                                                                     | Comparative study: 1.3% (compared to 1.7% universal screening; difference between the two NS)           |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Migrant clinic (n = 1) (sample size: 4078)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Coverage: 90.8%                                                                                                       | 3.6%                                                                                                    |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Pharmacies (n = 2) (sample size: 143 intervention, 561 control; 244 conventional care pathway; 262 pharmacist care pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Comparative study (DBS): 30% intervention; 13% control. OR: 2.25 (95% CI 1.48‐3.42)                                   | Comparative study: 25.9% conventional care pathway 26.5%; pharmacist care pathway                       |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparative study: 24% coverage conventional care pathway; 36% pharmacist care pathway                                |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Drug clinics and prisons (n = 1) (sample size: 6550 intervention, 5800 control)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparative study coverage (DBS) intervention: 8.4% before, 20.6% during intervention                                 | 32% (overall)                                                                                           |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | control: 7.7% before, 5.4% during intervention                                                                        |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Public health clinic (n = 1) (sample size: 81 and 497)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Coverage: 90% and 98%                                                                                                 | 60% (overall)                                                                                           |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Specialist services[b](#jvh13182-note-0009){ref-type="fn"} (n = 1) (sample size: 1322)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                       | 55%                                                                                                     |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Clinic for people with no health insurance (n = 1) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Number tested/tests: 1196                                                                                             | 5.8%                                                                                                    |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Coverage: 90% when screening is proposed during a prevention interview; 71% without interview                         |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Universal testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | **HCV**                                                                                                               |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[47](#jvh13182-bib-0047){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Antenatal services (n = 1) (No sample size)                                                                           | Number tested: 4222                                                                                     | Comparative study: 1.7%                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       |                                                                                                         | (compared to 1.3% targeted screening; difference between the two NS)   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Novel testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | **HBV**                                                                                                               |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 3 studies[44](#jvh13182-bib-0044){ref-type="ref"}, [50](#jvh13182-bib-0050){ref-type="ref"}, [56](#jvh13182-bib-0056){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Clinic for people with no health insurance (n = 1) (sample size: 162 intervention, 162 control)                       | Coverage: 64.2% (serology); 98.2% (RT)                                                                  | Comparative study: 9.6% (serology); 8.1% (RT)                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 1 study high                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 1 study acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 1 study NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Antenatal services (n = 1) (Sample size: 41 pre‐intervention; 58 post‐intervention; 91 pre‐control; 68 post‐control)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Comparative study:                                                                                                    | Comparative study:                                                                                      |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Coverage (DBS): 62% pre‐intervention; 97% post‐intervention; 40% pre‐control; 39% post‐control                        | 0%‐3% pre‐intervention; 3%‐22% post‐intervention; 6%‐8% pre‐control; 2%‐9% post‐control                 |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Prisons (n = 1) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Number tested (DBS): 160                                                                                              | 0%                                                                                                      |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 11 studies[35](#jvh13182-bib-0035){ref-type="ref"}, [42](#jvh13182-bib-0042){ref-type="ref"}, [43](#jvh13182-bib-0043){ref-type="ref"}, [44](#jvh13182-bib-0044){ref-type="ref"}, [45](#jvh13182-bib-0045){ref-type="ref"}, [49](#jvh13182-bib-0049){ref-type="ref"}, [52](#jvh13182-bib-0052){ref-type="ref"}, [56](#jvh13182-bib-0056){ref-type="ref"}, [58](#jvh13182-bib-0058){ref-type="ref"}, [59](#jvh13182-bib-0059){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}                                                                                                                                                                         | Clinic for people with no health insurance (n = 1) (sample size: 162 intervention, 162 control)                       | Coverage: 64.2% (serology); 98.2% (RT)                                                                  | Comparative study: 3.8% (serology); 2.5% (RT)                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 1 study high                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 4 studies acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 1 study low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 5 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Drug services (n = 3) (sample size: 25‐1123)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Number tested/tests (DBS): 266                                                                                        | 31.2% and 35%                                                                                           |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Coverage (FibroScan): 20%                                                                                             |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Coverage (DBS): 84.2%                                                                                                 |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Prisons (n = 2) (sample size: 3600[a](#jvh13182-note-0008){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Number tested (DBS): 160                                                                                              | 33.8%                                                                                                   |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparative study (DBS): ORs for effect of the intervention on testing rate: 0.86; 95% CI: 0.71‐1.06; *P* = 0.153     |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Drug clinics and prisons (n = 1) (sample size: 6550 intervention, 5800 control)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparative study coverage (DBS) intervention: 8.4% before, 20.6% during intervention                                 | 32% (overall)                                                                                           |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | control: 7.7% before, 5.4% during intervention                                                                        |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| STI clinics and GP practices (n = 1) (sample size: 29 600)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Coverage (oral): 15.2%                                                                                                | 0.6%                                                                                                    |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Specialist services[b](#jvh13182-note-0009){ref-type="fn"} (n = 1) (sample size: 1322)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                       | 55%                                                                                                     |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Pharmacies (n = 2) (sample size: 143 intervention, 561 control; 244 conventional care pathway; 262 pharmacist care pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Comparative study coverage (DBS): 30% intervention; 13% control. OR: 2.25 (95% CI 1.48‐3.42)                          | Comparative study: 25.9% conventional care pathway; 26.5% pharmacist care pathway                       |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparative study coverage (DBS): 24% conventional care pathway; 36% pharmacist care pathway                          |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Education                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | **HCV**                                                                                                               |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[42](#jvh13182-bib-0042){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Targeted at‐risk groups                                                                                               | Comparative study coverage: 7% control; 20% intervention (NS)                                           |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Drug services (n = 1) (sample size: 52)                                                                               | Willingness for HCV screening:                                                                          |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| High                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                       | Control: 89%; 56%; 67% (baseline; after 1 mo; after 3 mo)                                               |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       | Intervention: 86%; 96%; 100%; 77%; 100% (baseline; after info; after 1 mo; after 3 mo; after FibroScan) |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Campaign                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | **HCV**                                                                                                               |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 2 studies[34](#jvh13182-bib-0034){ref-type="ref"}, [46](#jvh13182-bib-0046){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Targeted at general pop.                                                                                              | Coverage from mixed settings: 2.3%‐3.7%                                                                 | Comparative study:                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Mixed settings (n = 1), STI clinic/Prison (n = 1)                                                                     |                                                                                                         | prison: 44.4% before, 27.0% during intervention                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| 2 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (sample size: 4200 and 33 667[a](#jvh13182-note-0008){ref-type="fn"})                                                 |                                                                                                         | STI clinic: 5.2% before, 3.5% during intervention                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         | 45%‐53% newly diagnosed                                                |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Guideline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | **HCV**                                                                                                               |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[53](#jvh13182-bib-0053){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | STI clinics (n = 1) (sample size: NR)                                                                                 | Comparative study:                                                                                      |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       | Coverage: 4.7% before, 13.6% after intervention                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Clinical decision‐making tools                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | **HBV**                                                                                                               |                                                                                                         |                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Computer‐assisted self/ personal interviewing (CASI/CAPI) vs paper & pen (PAPI, control)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[60](#jvh13182-bib-0060){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | STI clinic (n = 1) (sample size: 2318)                                                                                | Comparative study:                                                                                      | Comparative study:                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       | Coverage: PAPI: 16%; CAPI: 24%; CASI: 17%                                                               | Any STI: PAPI: 10%; CAPI: 11%; CASI: 10%                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| High                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| N = 1 study[60](#jvh13182-bib-0060){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | STI clinic (n = 1) (sample size: 2318)                                                                                | Comparative study:                                                                                      | Comparative study:                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                       | Coverage: PAPI: 3%; CAPI: 9%; CASI: 3%                                                                  | Any STI: PAPI: 10%; CAPI: 11%; CASI: 10%                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                       |                                                                                                         |                                                                        |
| High                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                       |                                                                                                         |                                                                        |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+

Abbreviations: BBV, bloodborne virus; CASI, computer‐assisted self‐interviewing; CAPI, computer‐assisted personal interviewing; CI, confidence interval; DBS, dried blood spot; GP, general practitioner; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; mo, months; MSM, men who have sex men; NA, not applicable; NS, not significant; OR, odds ratio; PAPI, pen‐and‐paper interviewing; RT, rapid test; STI, sexually transmitted infection.

Denominator not reported for all studies.

specialist services mainly targeting PWID.

Number of tests is only reported here if no data on coverage are available.
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Eleven comparative studies reported on interventions in other healthcare settings. In pharmacies, HCV testing coverage was 30% among drug users receiving opioid substitution therapy (OST) when DBS testing was offered, compared to 13% in pharmacies which did not offer DBS. Furthermore, DBS testing coverage was 36% in pharmacies in which pharmacist‐led care pathways were used compared to 24% when conventional care pathways were used.[58](#jvh13182-bib-0058){ref-type="ref"}, [59](#jvh13182-bib-0059){ref-type="ref"} One randomized controlled trial (RCT) found that offering DBS testing for HCV in drug clinics and prisons significantly increased coverage rates in intervention sites with a 14.5% increase compared to control sites[49](#jvh13182-bib-0049){ref-type="ref"}; however, another RCT in which DBS testing for HCV was offered in prisons found an OR of 0.86 (95% CI: 0.71‐1.06) for the effect of the intervention on testing rate.[45](#jvh13182-bib-0045){ref-type="ref"} Another comparative study reported a doubling in the number of tests performed in prisons and STI clinics during a national testing programme which involved awareness‐raising activities.[34](#jvh13182-bib-0034){ref-type="ref"} Point‐of‐care rapid testing in clinics for people without healthcare coverage was found to significantly increase testing coverage to 98.2%, compared to standard serology testing performed elsewhere which had 64.2% coverage.[44](#jvh13182-bib-0044){ref-type="ref"} One study which implemented testing of household contacts of HBV‐positive pregnant women through nurse‐led at‐home DBS testing reported a significant increase in coverage from 62% to 97% in antenatal services in which the intervention was implemented, compared to control sites where there was no increase observed in the same time frame.[50](#jvh13182-bib-0050){ref-type="ref"} Another comparative study compared universal and risk‐based HCV screening for pregnant women in antenatal services and reported a positivity rate of 1.7% for universal screening compared to 1.3% for targeted screening; the difference was not significant.[47](#jvh13182-bib-0047){ref-type="ref"} Information sessions and peer education increased coverage from 7% to 20% in a drug clinic, although this difference was not significant.[42](#jvh13182-bib-0042){ref-type="ref"} Introduction of a clinic‐specific guideline in an STI clinic led to an increase in coverage from 4.7% to 13.6%.[53](#jvh13182-bib-0053){ref-type="ref"} One comparative study reported on a clinical decision‐making tool initiative which included computer‐assisted self/personal interviewing vs paper‐and‐pen interviews in STI clinics. Both HBV and HCV testing coverage were highest (24% and 9%, respectively) after computer‐assisted personal interviewing.[60](#jvh13182-bib-0060){ref-type="ref"}

Acceptability and feasibility of testing initiatives in other healthcare settings were reported by three studies.[44](#jvh13182-bib-0044){ref-type="ref"}, [58](#jvh13182-bib-0058){ref-type="ref"}, [60](#jvh13182-bib-0060){ref-type="ref"} One study on rapid DBS testing for HCV in pharmacies showed that patients found the pharmacy a good place to be tested, but some patients were suspicious when offered testing due to previous experience of discrimination at pharmacies.[58](#jvh13182-bib-0058){ref-type="ref"} Among pharmacy staff, rapid DBS testing for HCV was found to be simple to perform. Rapid testing in a clinic for people with no health insurance was preferred over serological tests by 76% of the participants, with reasons including less stress with same‐day results and more practical use. Half of the clinical staff said that rapid testing simplified their consultation.[44](#jvh13182-bib-0044){ref-type="ref"} A study that compared computer‐assisted interviewing to paper‐and‐pen interviews in STI clinics found that computer‐assisted interviewing encouraged the disclosure of sexual risk‐taking behaviour more.[60](#jvh13182-bib-0060){ref-type="ref"}

3.4. Testing initiatives in community settings {#jvh13182-sec-0010}
----------------------------------------------

Forty‐one studies were retrieved that formed the evidence base for the effectiveness of testing initiatives and interventions in community settings.[34](#jvh13182-bib-0034){ref-type="ref"}, [43](#jvh13182-bib-0043){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}, [65](#jvh13182-bib-0065){ref-type="ref"}, [66](#jvh13182-bib-0066){ref-type="ref"}, [67](#jvh13182-bib-0067){ref-type="ref"}, [68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [70](#jvh13182-bib-0070){ref-type="ref"}, [71](#jvh13182-bib-0071){ref-type="ref"}, [72](#jvh13182-bib-0072){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [77](#jvh13182-bib-0077){ref-type="ref"}, [78](#jvh13182-bib-0078){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [80](#jvh13182-bib-0080){ref-type="ref"}, [81](#jvh13182-bib-0081){ref-type="ref"}, [82](#jvh13182-bib-0082){ref-type="ref"}, [83](#jvh13182-bib-0083){ref-type="ref"}, [84](#jvh13182-bib-0084){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [86](#jvh13182-bib-0086){ref-type="ref"}, [87](#jvh13182-bib-0087){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"} Results of initiatives performed in community settings are presented in Table [4](#jvh13182-tbl-0004){ref-type="table"}. Results for all intervention types are presented first, stratified by setting type.

###### 

Evidence base for the effectiveness of testing initiatives in community settings

+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Studies included                                                                                                                                   | Target population                                                                                                                                                                                              | Test offer                                                                                                                                                          | Coverage/number of tests/tested[c](#jvh13182-note-0014){ref-type="fn"}                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Quality of evidence                                                                                                                                |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+====================================================================================================================================================+================================================================================================================================================================================================================+=====================================================================================================================================================================+============================================================================================================================================================+
| All per setting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | **HBV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 18 studies [65](#jvh13182-bib-0065){ref-type="ref"}, [66](#jvh13182-bib-0066){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [72](#jvh13182-bib-0072){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [78](#jvh13182-bib-0078){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [82](#jvh13182-bib-0082){ref-type="ref"}, [83](#jvh13182-bib-0083){ref-type="ref"}, [84](#jvh13182-bib-0084){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [86](#jvh13182-bib-0086){ref-type="ref"}, [87](#jvh13182-bib-0087){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}                                                                                                                                                                                                                  | Community‐based testing sites (n = 2) (sample size: 512 and 744)                                                                                   |                                                                                                                                                                                                                | Coverage: 37% and 71.1%                                                                                                                                             | 8.3% and 9.4%                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 3 studies acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 15 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Outreach (n = 11) (sample size: 30‐86 000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 100%                                                                                                                                               | Number tested/tests: 299‐1090                                                                                                                                                                                  | 0%‐12.4%                                                                                                                                                            |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 9.8%‐76.2%                                                                                                                                                                                           | Comparative study: 0% control; 2.1% intervention (outreach education + testing at health centre); 4.8% intervention (outreach education + onsite test)              |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: 1.5% control; 42.8% intervention (outreach education + testing at health centre); 59.7% intervention (outreach education + onsite test)                                            |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study: Coverage: 53.3% DBS postal kit; 83.3% nurse‐led sauna outreach testing; 100% standard STI clinic testing                                                                                    |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Drug services/ harm reduction programmes (n = 2) (sample size: intervention 27, control 28; 391)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                    | Coverage: 49%                                                                                                                                                                                                  | 20% (anti‐HBc)                                                                                                                                                      |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: Intervention (oral) 92.6%; control (referral) 7.4%                                                                                                                                 |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Online tools (n = 3) (sample size: 265 and 1400[a](#jvh13182-note-0012){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    | Coverage: 16.2%                                                                                                                                                                                                | 0% and 0.2%                                                                                                                                                         |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | 4305 self‐sampling kits requested; 48% of requested kits returned                                                                                                                                              |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: 43.9% intervention (behavioural tailoring plus cultural tailoring) (OR 0.94 95% CI 0.69‐1.26); 43.5% intervention (behavioural tailoring) (OR 0.88 95% CI 0.65‐1.19) 46.0% control |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 23 studies[34](#jvh13182-bib-0034){ref-type="ref"}, [43](#jvh13182-bib-0043){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}, [65](#jvh13182-bib-0065){ref-type="ref"}, [67](#jvh13182-bib-0067){ref-type="ref"}, [68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [70](#jvh13182-bib-0070){ref-type="ref"}, [71](#jvh13182-bib-0071){ref-type="ref"}, [72](#jvh13182-bib-0072){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [77](#jvh13182-bib-0077){ref-type="ref"}, [78](#jvh13182-bib-0078){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [80](#jvh13182-bib-0080){ref-type="ref"}, [81](#jvh13182-bib-0081){ref-type="ref"}, [82](#jvh13182-bib-0082){ref-type="ref"}, [83](#jvh13182-bib-0083){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"} | Community‐based testing sites (n = 3) (sample size: 32‐744)                                                                                        |                                                                                                                                                                                                                | Number tested/tests: 95                                                                                                                                             | 0%‐6.3%                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                    |                                                                                                                                                                                                                | Coverage: 37% and 71.1%                                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 3 studies acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 20 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Outreach (n = 7) (sample size: 30‐65 000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 100%                                                                                                                                               | Number tested/tests: 491‐520                                                                                                                                                                                   | 0.8%‐37.6%                                                                                                                                                          |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 9.8%‐76.2%                                                                                                                                                                                           | Comparative study: 0% control; 3.2% intervention (outreach education + testing at health centre); 2.8% intervention (outreach education + onsite test)              |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: 1.5% control; 42.8% intervention (outreach education + testing at health centre); 59.7% intervention (outreach education + onsite test)                                            | Comparative study: HBV/HCV active; cleared infection                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: Coverage: 53.3% DBS postal kit; 83.3% nurse‐led sauna outreach testing; 100% standard STI clinic testing                                                                           | 6.25%; 25% DBS postal kits                                                                                                                                          |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 4% nurse‐led sauna outreach testing                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 0% standard STI clinic testing                                                                                                                                  |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Drug services/harm reduction programmes (n = 8) (sample size: 27‐5399)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                    | Comparative study: 67 tests before 973 during                                                                                                                                                                  | 18%‐53%                                                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 42%‐84.2%                                                                                                                                                                                            | Comparative study: 15% intervention; 14% control                                                                                                                    |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: Intervention (oral) 100%; control (referral) 7.4%                                                                                                                                  | Comparative study: 19.4% before; 38.1% during                                                                                                                       |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study: 44% intervention; 51% control                                                                                                                                                               |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Online tools (n = 2) (sample size: 265 and 9653)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15.3%                                                                                                                                              | Coverage: 4.4% and 16.2%                                                                                                                                                                                       | 4.5% and 4.6%                                                                                                                                                       |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Combined settings (n = 3) (sample size: 240 and 564[a](#jvh13182-note-0012){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 73%                                                                                                                                                | Number tested/tests: 266                                                                                                                                                                                       | 4.8%‐35%                                                                                                                                                            |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 37% and 72%                                                                                                                                                                                          |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Risk group testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | **HBV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 16 studies[65](#jvh13182-bib-0065){ref-type="ref"}, [66](#jvh13182-bib-0066){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [72](#jvh13182-bib-0072){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [78](#jvh13182-bib-0078){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [82](#jvh13182-bib-0082){ref-type="ref"}, [83](#jvh13182-bib-0083){ref-type="ref"}, [84](#jvh13182-bib-0084){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [86](#jvh13182-bib-0086){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}                                                                                                                                                                                                                                                                                                       | Drug users (n = 3) (sample size: intervention 27, control 28; 391[a](#jvh13182-note-0012){ref-type="fn"})                                          | 100%                                                                                                                                                                                                           | Coverage: 49%‐76.2%                                                                                                                                                 | 0%                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                    |                                                                                                                                                                                                                | Comparative study coverage: intervention (oral) 92.6%; control (referral) 7.4%                                                                                      | 20% (anti‐HBc)                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 3 studies acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 13 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Homeless (n = 1) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                    | Number tested/tests: 491                                                                                                                                                                                       | 12.4%                                                                                                                                                               |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Migrants (n = 9) (sample size: 744‐65 000[a](#jvh13182-note-0012){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                    | Number tested/tests: 299‐1090                                                                                                                                                                                  | 0.6%‐8.7%                                                                                                                                                           |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 9.8%‐71.1%                                                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study coverage: 43.9% intervention (behavioural tailoring plus cultural tailoring) (OR 0.94 95% CI 0.69‐1.26); 43.5% intervention (behavioural tailoring) (OR 0.88 95% CI 0.65‐1.19) 46.0% control |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| MSM (n = 2) (sample size: 30‐265)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                    | Coverage: 16.2%                                                                                                                                                                                                | 0%                                                                                                                                                                  |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study: coverage: 53.3% DBS postal kit; 83.3% outreach sauna nurse; 100% standard STI clinic                                                                                                        | Comparative study: HBV/HCV active; cleared infection                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 6.25%; 25% DBS postal kits                                                                                                                                          |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 4% nurse‐led sauna outreach testing                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 0% standard STI clinic testing                                                                                                                                  |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Underprivileged people[b](#jvh13182-note-0013){ref-type="fn"} (n = 1) (sample size: 811 control; 222 intervention; 243 intervention + onsite test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                    | Comparative study coverage: 1.5% control; 42.8% intervention (outreach education + testing at health centre); 59.7% intervention (outreach education + onsite test)                                            | Comparative study: 0% control; 2.1% intervention (outreach education + testing at health centre); 4.8% intervention (outreach education + onsite test)              |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 20 studies [43](#jvh13182-bib-0043){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}, [65](#jvh13182-bib-0065){ref-type="ref"}, [67](#jvh13182-bib-0067){ref-type="ref"}, [68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [70](#jvh13182-bib-0070){ref-type="ref"}, [71](#jvh13182-bib-0071){ref-type="ref"}, [72](#jvh13182-bib-0072){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [78](#jvh13182-bib-0078){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [80](#jvh13182-bib-0080){ref-type="ref"}, [81](#jvh13182-bib-0081){ref-type="ref"}, [82](#jvh13182-bib-0082){ref-type="ref"}, [83](#jvh13182-bib-0083){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"}                                                                                                                              | Drug users (n = 6) (sample size: 27‐9653)                                                                                                          | 100%                                                                                                                                                                                                           | Number tested/tests: 266                                                                                                                                            | 31.2%‐41%                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                    |                                                                                                                                                                                                                | Coverage: 49%‐84.2%                                                                                                                                                 |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 2 studies acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                    |                                                                                                                                                                                                                | Comparative study coverage: intervention (oral) 100%; control (referral) 7.4%                                                                                       |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 18 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| PWID (n = 3) (sample size: 240 and 3463[a](#jvh13182-note-0012){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 73%                                                                                                                                                | Number tested/tests: 24‐202                                                                                                                                                                                    | 18% and 20.3%                                                                                                                                                       |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 42% and 72%                                                                                                                                                                                          |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Homeless (n = 2) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                    | Number tested/tests: 95‐491                                                                                                                                                                                    | 6.3% and 13%                                                                                                                                                        |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Migrants (n = 5) (sample size: 744‐65 000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                    | Number tested/tests: 520                                                                                                                                                                                       | 0.3%‐4.7%                                                                                                                                                           |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 9.8%‐71.1%                                                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| MSM (n = 2) (sample size: 30‐265)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                    | Coverage: 16.2%                                                                                                                                                                                                | 4.6%                                                                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Comparative study: coverage: 53.3% DBS postal kit; 83.3% outreach sauna nurse; 100% standard STI clinic                                                                                                        | Comparative study: HBV/HCV active; cleared infection                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 6.25%; 25% DBS postal kits                                                                                                                                          |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 4% nurse‐led sauna outreach testing                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 0% standard STI clinic testing                                                                                                                                  |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Underprivileged people[b](#jvh13182-note-0013){ref-type="fn"} (n = 1) (sample size: 811 control; 222 intervention; 243 intervention + onsite test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                    | Comparative study coverage: 1.5% control; 42.8% intervention (outreach education + testing at health centre); 59.7% intervention (outreach education + onsite test)                                            | Comparative study: 0% control; 3.2% intervention (outreach education + testing at health centre); 2.8% intervention (outreach education + onsite test)              |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Risk groups (n = 1) (sample size: 9653)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15.3%                                                                                                                                              | Coverage: 4.4%                                                                                                                                                                                                 | 4.5%                                                                                                                                                                |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Novel testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | **HBV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 8 studies [65](#jvh13182-bib-0065){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [87](#jvh13182-bib-0087){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Drug users (n = 3) (sample size: intervention 27, control 28; 391[a](#jvh13182-note-0012){ref-type="fn"})                                          | 100%                                                                                                                                                                                                           | Coverage (DBS): 49%                                                                                                                                                 | 0%                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                    |                                                                                                                                                                                                                | Coverage (FibroScan): 76.2%                                                                                                                                         | 20% (anti‐HBc)                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 1 study acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                    |                                                                                                                                                                                                                | Comparative study coverage: intervention (oral) 92.6%; control (referral) 7.4%                                                                                      |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 7 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Migrants (n = 2) (sample size: 21 000 and 65 000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                    | Number tested/tests (DBS): 229‐1126                                                                                                                                                                            | 8.7%                                                                                                                                                                |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| MSM (n = 1) (sample size: 30 per group)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    | Comparative study: coverage: 53.3% DBS postal kit; 83.3% outreach sauna nurse; 100% standard STI clinic                                                                                                        | Comparative study: HBV/HCV active; cleared infection                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 6.25%; 25% DBS postal kits                                                                                                                                          |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 4% nurse‐led sauna outreach testing                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 0% standard STI clinic testing                                                                                                                                  |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Students (n = 1) (sample size: 512)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                    | Coverage (DBS): 37%                                                                                                                                                                                            | 9.4%                                                                                                                                                                |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| General pop (n = 1) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                    | 4305 self‐sampling kits requested; 48% of requested kits returned                                                                                                                                              | 0.2%                                                                                                                                                                |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 13 studies[34](#jvh13182-bib-0034){ref-type="ref"}, [43](#jvh13182-bib-0043){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}, [65](#jvh13182-bib-0065){ref-type="ref"}, [67](#jvh13182-bib-0067){ref-type="ref"}, [68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [80](#jvh13182-bib-0080){ref-type="ref"}, [81](#jvh13182-bib-0081){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                     | Drug users (n = 7) (Sample size: 27‐1123)                                                                                                          |                                                                                                                                                                                                                | Number tested/tests (DBS): 266                                                                                                                                      | 27.5%‐53%                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                    |                                                                                                                                                                                                                | Coverage (DBS): 13%‐49%                                                                                                                                             | Comparative study (DBS): 12‐fold increase in positives (RR = 12.1, *P* \< 0.001)                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 1 study acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                    |                                                                                                                                                                                                                | Coverage (FibroScan): 76.2%                                                                                                                                         |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 12 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                    |                                                                                                                                                                                                                | Comparative study coverage: Intervention (oral) 100%; control (referral) 7.4%                                                                                       |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | Comparative study (DBS): 3‐fold increase in testing (RR = 3.5, *P* \< 0.001)                                                                                        |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| PWID (n = 2) (sample size: 240[a](#jvh13182-note-0012){ref-type="fn"})                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 73% (oral)                                                                                                                                         | Number tested/tests (DBS): 202                                                                                                                                                                                 | 20.3% (oral)                                                                                                                                                        |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage (oral): 72%                                                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Homeless (n = 1) (sample size: NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                    | Number tested/tests (DBS): 95                                                                                                                                                                                  | 6.3%                                                                                                                                                                |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Migrants (n = 1) (sample size: 65 000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                    | Number tested/tests (DBS): 520                                                                                                                                                                                 | 0.8%                                                                                                                                                                |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| MSM (n = 1) (sample size: 30 per group)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    | Comparative study: coverage: 53.3% DBS postal kit; 83.3% outreach sauna nurse; 100% standard STI clinic                                                                                                        | Comparative study: HBV/HCV active; cleared infection                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 6.25%; 25% DBS postal kits                                                                                                                                          |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 4% nurse‐led sauna outreach testing                                                                                                                             |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                | 0%; 0% standard STI clinic testing                                                                                                                                  |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Students (n = 1) (sample size: 512)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                    | Coverage (DBS): 37%                                                                                                                                                                                            | 0%                                                                                                                                                                  |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Education                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | **HBV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 3 studies [76](#jvh13182-bib-0076){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Targeted at‐risk groups                                                                                                                            |                                                                                                                                                                                                                | Coverage: 11.2% and 31%                                                                                                                                             | 1.1% and 2.8%                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Underprivileged people[b](#jvh13182-note-0013){ref-type="fn"} (n = 1) (sample size: 811 control; 222 intervention; 243 intervention + onsite test) |                                                                                                                                                                                                                | Comparative study coverage: 1.5% control; 42.8% intervention (outreach education + testing at health centre); 59.7% intervention (outreach education + onsite test) | Comparative study 0% control; 2.1% intervention (outreach education + testing at health centre); 4.8% intervention (outreach education + onsite test)      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 1 study acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Migrants (n = 2) (sample size: 1500 and 6337                                                                                                       |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 2 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 4 studies[76](#jvh13182-bib-0076){ref-type="ref"}, [77](#jvh13182-bib-0077){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Targeted at‐risk groups                                                                                                                            |                                                                                                                                                                                                                | Coverage: 11.2% and 31%                                                                                                                                             | 0.3% and 2.4%                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Underprivileged people[b](#jvh13182-note-0013){ref-type="fn"} (n = 1) (sample size: 811 control; 222 intervention; 243 intervention + onsite test) |                                                                                                                                                                                                                | Comparative study coverage: 1.5% control; 42.8% intervention (outreach education + testing at health centre); 59.7% intervention (outreach education + onsite test) | Comparative study HCV: 0% control; 3.2% intervention (outreach education + testing at health centre); 2.8% intervention (outreach education + onsite test) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 1 study acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Migrants (n = 2) (sample size: 1500 and 6337)                                                                                                      |                                                                                                                                                                                                                | Comparative study: 78% control; 85% intervention                                                                                                                    | Comparative study: 14% control; 15% intervention                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 3 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PWID (n = 1) (sample size: 88)                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Campaign                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | **HBV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 4 studies[66](#jvh13182-bib-0066){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [86](#jvh13182-bib-0086){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Targeted at‐risk groups                                                                                                                            |                                                                                                                                                                                                                | Number tested/tests: 299 and 1090                                                                                                                                   | 2.8%‐8.7%                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Migrants (n = 4)                                                                                                                                   |                                                                                                                                                                                                                | Coverage: 11.2% and 15.3%                                                                                                                                           | 2.9% newly diagnosed                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 4 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (sample size: 6337‐29 000)                                                                                                                         |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 3 studies [34](#jvh13182-bib-0034){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Targeted at‐risk groups                                                                                                                            |                                                                                                                                                                                                                | Coverage: 11.2%                                                                                                                                                     | 0.3%                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Migrants (n = 1) (sample size: 6337)                                                                                                               |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 3 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Targeted at GPs and those at risk General pop. (n = 1) (sample size: 5339)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                    | Comparative study number tested/tests: 67 before; 973 during                                                                                                                                                   | Comparative study: 19.4% before; 38.1% during                                                                                                                       |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Targeted at public General pop. (n = 1) (sample size: 9653)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                    | 15.3% website visitors offered testing.                                                                                                                                                                        | 4.5%                                                                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 4.4%                                                                                                                                                                                                 |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| National programme                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | **HCV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 2 studies[34](#jvh13182-bib-0034){ref-type="ref"}, [70](#jvh13182-bib-0070){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | PWID (n = 1)                                                                                                                                       |                                                                                                                                                                                                                | Coverage: 42%                                                                                                                                                       | 18%                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (sample size: 3463)                                                                                                                                |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 2 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| General population (n = 1) (sample size: 5399)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                    | Comparative study: coverage before and after programme: 26% (in 2000); 62% (in 2008)                                                                                                                           | Comparative study: 19.4% before; 38.1% during                                                                                                                       |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Communication & technology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | **HBV**                                                                                                                                            |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 2 studies[78](#jvh13182-bib-0078){ref-type="ref"}, [84](#jvh13182-bib-0084){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | MSM (n = 1)                                                                                                                                        |                                                                                                                                                                                                                | Coverage: 16.2%                                                                                                                                                     | 0%                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (sample size: 265)                                                                                                                                 |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 1 study acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 1 study NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Migrants (n = 1) (HCV n = 0, HBV n = 1 sample:432‐496)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                    | Comparative study coverage:                                                                                                                                                                                    |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | 43.9% BCT; 43.5% BT; 46.0% GI                                                                                                                                                                                  |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | ORs (95%CI):                                                                                                                                                                                                   |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | BCT vs GI: 0.94 (0.69‐1.26)                                                                                                                                                                                    |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | BT vs GI: 0.88 (0.65‐1.19)                                                                                                                                                                                     |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **HCV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| N = 2 studies[78](#jvh13182-bib-0078){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | MSM (n = 1)                                                                                                                                        |                                                                                                                                                                                                                | Coverage: 16.2%                                                                                                                                                     | 4.6%                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| Quality:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (sample size: 265)                                                                                                                                 |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
| 2 studies NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| General population (n = 1) (sample size: 9653)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                    | 15.3% website visitors offered testing.                                                                                                                                                                        | 4.5%                                                                                                                                                                |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    | Coverage: 4.4%                                                                                                                                                                                                 |                                                                                                                                                                     |                                                                                                                                                            |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+

Abbreviations: anti‐HBC, antibody to the hepatitis B core antigen; BCT, behavioural plus cultural tailoring; BT, behavioural tailoring; CI, confidence interval; DBS, dried blood spot; GI, generic information; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MSM, men who have sex with men; NA, not applicable; OR, odds ratio; PWID, people who inject drugs; STI, sexually transmitted infection; TB, tuberculosis.

Denominator not reported by all studies.

Unemployed, social assistance beneficiaries and seekers of political asylum living in long‐term shelters.

Number of tests is only reported here if no data on coverage is available.

John Wiley & Sons, Ltd

Coverage rates above 80% were reported by two testing initiatives conducted in community drugs services,[64](#jvh13182-bib-0064){ref-type="ref"}, [65](#jvh13182-bib-0065){ref-type="ref"} although the other six studies conducted in this setting reported lower coverage. HCV positivity rates were high in this setting.[34](#jvh13182-bib-0034){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}, [70](#jvh13182-bib-0070){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [77](#jvh13182-bib-0077){ref-type="ref"}, [81](#jvh13182-bib-0081){ref-type="ref"} Outreach testing activities and testing initiatives conducted in fixed community sites yielded coverage rates of up to 83.3% and 71.1%, respectively.[66](#jvh13182-bib-0066){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [72](#jvh13182-bib-0072){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [76](#jvh13182-bib-0076){ref-type="ref"}, [79](#jvh13182-bib-0079){ref-type="ref"}, [80](#jvh13182-bib-0080){ref-type="ref"}, [82](#jvh13182-bib-0082){ref-type="ref"}, [83](#jvh13182-bib-0083){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [86](#jvh13182-bib-0086){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}, [89](#jvh13182-bib-0089){ref-type="ref"} In general, online testing initiatives reported somewhat lower coverage rates relative to other settings (4.4% and 16.2%),[78](#jvh13182-bib-0078){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"} as well as low positivity rates for HBV (0% and 0.2%). Across all settings, novel testing initiatives yielded relatively high coverage rates in general, with eight out of fourteen studies that reported coverage testing more than 50% of the targeted population.[34](#jvh13182-bib-0034){ref-type="ref"}, [43](#jvh13182-bib-0043){ref-type="ref"}, [64](#jvh13182-bib-0064){ref-type="ref"}, [65](#jvh13182-bib-0065){ref-type="ref"}, [67](#jvh13182-bib-0067){ref-type="ref"}, [68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [73](#jvh13182-bib-0073){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [75](#jvh13182-bib-0075){ref-type="ref"}, [80](#jvh13182-bib-0080){ref-type="ref"}, [81](#jvh13182-bib-0081){ref-type="ref"}, [85](#jvh13182-bib-0085){ref-type="ref"}, [87](#jvh13182-bib-0087){ref-type="ref"}, [88](#jvh13182-bib-0088){ref-type="ref"}

Two comparative studies reported on novel testing initiatives targeted to risk groups. In community drug services, onsite oral sampling of drug users had a reported coverage of 100%, compared to 7.4% for standard serological testing which was performed offsite, at an STI clinic.[65](#jvh13182-bib-0065){ref-type="ref"} Another study compared nurse‐delivered outreach screening at a sauna and self‐sampled DBS postal testing kits to standard screening at an STI clinic for MSM and reported coverage rates for the first 30 users of each service: 83.3% for outreach, 53.3% for DBS postal kits and 100% for standard screening. Positivity rates were higher for outreach (4% had a cleared HBV or HCV infection) and DBS postal kits (25% had a cleared HBV or HCV infection), compared to 0% for those tested in STI clinics. In addition, almost all STI clinic users had been tested previously, compared to just over half of sauna and postal kit users.[88](#jvh13182-bib-0088){ref-type="ref"}

An RCT compared outreach testing in shelters for underprivileged people, involving group education sessions and individual consultations during which subjects were offered testing, either at a health centre or onsite. Coverage was 42.8% at healthcare centres and 59.7% onsite. Coverage in a control group that received no intervention during the same time period was 1.5%.[79](#jvh13182-bib-0079){ref-type="ref"} Educational sessions for PWID attending harm reduction centres contributed to an increased coverage from 44% to 85%, compared to an increase of 51 to 78% in a control group that received no educational intervention.[77](#jvh13182-bib-0077){ref-type="ref"} During an HCV action plan in Scotland, implementation of DBS testing and awareness activities resulted in a 3‐fold increase in HCV testing coverage in community drug services (RR 3.5, *P* \< 0.001) and a 12‐fold increase in positive test results (RR = 12.1, *P* \< 0.001).In England, a national framework of activities to improve prevention, diagnosis and treatment of HCV led to an increase from 26% coverage in 2000 (prior to the national programme) to 62% coverage in 2008.[34](#jvh13182-bib-0034){ref-type="ref"}, [70](#jvh13182-bib-0070){ref-type="ref"} Lastly, a communication and technology HBV testing initiative involving Internet‐based recruitment of migrants for screening yielded coverage of 43.5%‐46.0%, although comparison between different strategies (behavioural tailoring, behavioural plus cultural tailoring or generic information) showed no differences.[84](#jvh13182-bib-0084){ref-type="ref"}

Eight studies provided data on the feasibility and acceptability of testing in community settings. Test acceptance rates ranged from 28.4% to 98.2%[68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"}, [74](#jvh13182-bib-0074){ref-type="ref"}, [90](#jvh13182-bib-0090){ref-type="ref"} with the highest rates reported in two studies which described outreach initiatives targeting drug users, one of which used oral sampling.[68](#jvh13182-bib-0068){ref-type="ref"}, [69](#jvh13182-bib-0069){ref-type="ref"} Another study reporting on an outreach testing initiative targeted at Chinese migrants reported that 100% of interviewed recipients found an information session prior to testing useful and just 5% responded that the test caused discomfort.[85](#jvh13182-bib-0085){ref-type="ref"} A study describing an oral sampling initiative at a homeless shelter reported that 91% of the participants would agree to screening or thought an oral swab test was acceptable form of testing.[80](#jvh13182-bib-0080){ref-type="ref"} An online platform offering home sampling kits for HBV, HIV and STIs reported that of the samples returned, 15% were provided insufficient blood and 39% of participants reported difficulties taking blood samples. However, 95% said they would use the online service again and 93% would recommend it to family and friends.[87](#jvh13182-bib-0087){ref-type="ref"} A testing initiative targeted at university students with an acceptance rate of 37% reported that there was no indication or reports from students or staff that the testing offer and process were stigmatizing or undesirable.[74](#jvh13182-bib-0074){ref-type="ref"} Lastly, a culturally targeted screening project involving campaigns and educational meetings for Turkish migrants was considered good and understandable by 97% of the participants.[76](#jvh13182-bib-0076){ref-type="ref"}

3.5. Testing initiatives in multiple/unspecified settings {#jvh13182-sec-0011}
---------------------------------------------------------

In addition, two studies were retrieved which provided data on initiatives conducted in multiple settings or did not specify results per setting. One study examined the outcomes of a French national HCV prevention programme implemented in 1999 and reported that testing increased from 2000 to 2005 by 45% but decreased by 10% in 2006. Positivity rates decreased from 4.3% to 2.9%.[91](#jvh13182-bib-0091){ref-type="ref"} A further study describing a national testing programme which involved awareness‐raising activities reported outcomes across all settings; 19 058 tests were taken before; and 29 045 tests were taken during the programme and positivity rates decreased from 9.6% to 6.8%.[34](#jvh13182-bib-0034){ref-type="ref"}

4. DISCUSSION {#jvh13182-sec-0012}
=============

We undertook a comprehensive systematic review to collect, synthesize and analyse available data on HBV/HCV testing strategies across the EU/EEA. Available evidence on testing strategies was analysed qualitatively across primary health care, hospital settings, other healthcare settings and community settings.

Primary health care is usually the first point of contact that patients will have with the health care system. Therefore, it is an important setting for testing a number of population groups that may not present to other settings and may be especially important for specific population groups including ex‐PWID.[92](#jvh13182-bib-0092){ref-type="ref"} However, according to a UK study, of all HCV diagnostic tests performed in a pool of sentinel laboratories, only 16% were requested by GPs.[93](#jvh13182-bib-0093){ref-type="ref"} Overall, the evidence retrieved on the effectiveness of testing interventions to improve HBV and HCV testing coverage in primary health care was limited, largely restricted to Western European countries, and focused mainly on targeted test offer to risk groups such as migrants, PWID and homeless. A previous meta‐analysis assessing the effectiveness of targeted HCV testing interventions found these strategies to be effective in diagnosing cases and increasing uptake of treatment, particularly when strategies involved practitioners.[18](#jvh13182-bib-0018){ref-type="ref"} In this review, limited evidence indicated that educational interventions targeting GPs and campaigns targeting the public, GPs or risk groups may have benefit, particularly when education and campaigns are combined, and that offering HCV testing in this setting was acceptable to patients. A recent EU‐funded project investigated options to further expand testing opportunities for migrant communities in this setting and has produced a useful toolkit that may support its implementation.[94](#jvh13182-bib-0094){ref-type="ref"}

Hospitals are another important location for testing, with more than half of all HCV tests performed in UK sentinel laboratories requested by hospital‐based clinicians, especially hepatology and infectious disease departments.[93](#jvh13182-bib-0093){ref-type="ref"} However, the evidence on testing interventions aimed at improving HBV and HCV testing in hospital settings retrieved was relatively limited. In many studies, testing for HBV and HCV was performed as part of a BBV screening test including HIV testing. Specific hospital departments could be strategic settings to capture patients belonging to certain risk groups and encourage and facilitate testing. Targeted testing to individuals from risk groups (migrants and psychiatric patients) was implemented in hospital departments with generally high positivity rates and fairly high coverage levels in studies involving hospital inpatients or outpatients attending the hospital for reasons other than testing, although uptake was lower when participants were invited to come to the hospital for the sole purpose of testing. This emphasizes the importance of practitioners considering opportunistic test offer for patients that may be at risk. Two studies on universal testing in emergency departments reported lower positivity rates compared to other strategies; however, this could be an important strategy for case finding in areas that are known to have a high prevalence or burden of disease, or where injecting drug use is prevalent.

Evidence relating to other healthcare settings found similar variation in coverage and positivity rates which were often high when risk groups were targeted. This suggests that offering testing to groups at high risk of infection at locations they specifically attend for health purposes, such as health clinics for migrants, could be an effective method for case finding. Locations frequently visited by certain groups, where staff are medically trained, present an opportunity that can be exploited for testing. For example, individuals receiving OST access pharmacies on a regular basis to receive medication. People receiving OST were found to be more likely to accept DBS testing at the pharmacy than testing from other providers.[58](#jvh13182-bib-0058){ref-type="ref"} Furthermore, pharmacies in some countries can provide treatment for those found to be infected.[59](#jvh13182-bib-0059){ref-type="ref"} Novel testing approaches such as rapid testing and DBS were frequently employed in testing initiatives in the various healthcare settings and were found to be effective in increasing coverage in a number of comparative settings, as well as being highly acceptable among users and testing staff. Rapid testing allows point‐of‐care testing, simplifying the testing process as those tested do not have to visit outside testing centres or wait to pick up results, although it is crucial to ensure that individuals testing positive are linked to ongoing care. Another strategy identified that may help to improve testing coverage in other healthcare settings included implementation of clinic‐specific guidelines.[53](#jvh13182-bib-0053){ref-type="ref"} These may be particularly useful in countries where national hepatitis testing guidelines are not available.[8](#jvh13182-bib-0008){ref-type="ref"}

Community‐based testing services, both fixed‐site and outreach‐based, represent potential sites to target specific population groups and individuals who may be at increased risk of infection and who are not in contact with formal health services. Testing in community settings can be adapted and made accessible for these groups in order to maximize testing uptake[15](#jvh13182-bib-0015){ref-type="ref"}; however, a gap in policy on community and outreach testing was reported by some EU countries suggesting that it is not always implemented at scale.[8](#jvh13182-bib-0008){ref-type="ref"} Yet, we identified considerable evidence supporting the implementation of community‐based testing services. According to the evidence, testing services in community settings often resulted in high coverage and high positivity rates, particularly when targeting MSM, people with migration background and drug users, although influenced by the underlying epidemiology. Outreach activities, including short‐term testing facilities, mobile testing services and street‐based outreach, were also shown to be highly effective in targeting these population groups, while being highly adaptable. Available evidence also suggested that use of oral sampling and DBS increase testing coverage and oral sampling was considered acceptable in community‐based services. Compared to other infectious diseases, the market for HBV and HCV rapid tests is less abundant, and the scale of implementation is comparatively limited.[8](#jvh13182-bib-0008){ref-type="ref"} However, DBS and rapid tests are recommended by the WHO to facilitate testing in settings where no laboratory is available.[95](#jvh13182-bib-0095){ref-type="ref"} Finally, educational interventions, campaigns and national programmes were also found to increase community‐based testing coverage for HBV and HCV, including among migrant communities. An earlier systematic review on chronic HBV testing in community settings identified common features of successful screening interventions that included strategies to increase community awareness and knowledge and incorporated the target population\'s values in the design and implementation of the programme and were able to provide low cost or free access to care.[21](#jvh13182-bib-0021){ref-type="ref"}

Contact tracing and partner notification for HBV and HCV have recognized public health benefits, such as controlling the spread, reducing morbidity and mortality, reaching people with asymptomatic infection and people who do not present for diagnosis, counselling and treatment[96](#jvh13182-bib-0096){ref-type="ref"} and have been shown to be effective.[50](#jvh13182-bib-0050){ref-type="ref"} Partner notification may be implemented in different ways,[97](#jvh13182-bib-0097){ref-type="ref"} and approaches designed to meet diverse structural, societal and legal barriers. However, our study identified very limited evidence on this approach, possibly due to its suboptimal implementation in EU/EEA, as reported in a previous study.[98](#jvh13182-bib-0098){ref-type="ref"}

A recent WHO guideline recommended that HCV screening in birth cohorts of older persons at higher risk of infection and morbidity may be applied in populations with overall lower general prevalence, where indicated by the local epidemiology.[95](#jvh13182-bib-0095){ref-type="ref"}, [99](#jvh13182-bib-0099){ref-type="ref"} Recent epidemiological studies to assess the relevance of such an approach have been performed in some EU/EEA countries, demonstrating the growing interest in this testing strategy and suggesting a possible role of this approach in the elimination effort.[100](#jvh13182-bib-0100){ref-type="ref"}, [101](#jvh13182-bib-0101){ref-type="ref"}, [102](#jvh13182-bib-0102){ref-type="ref"}, [103](#jvh13182-bib-0103){ref-type="ref"} The evidence resulting from our study, however, indicated that the utility of birth cohort screening is dependent on the local epidemiology and context of the screening.

Self‐sampling and self‐testing are relatively new testing modalities that have the potential to increase testing coverage. For HIV, use of self‐sampling or self‐testing kits is already authorized in a limited number of countries.[104](#jvh13182-bib-0104){ref-type="ref"} For HIV, self‐testing has been associated with increased testing uptake among men in a number of RCTs and is recommended as a testing approach by the WHO.[105](#jvh13182-bib-0105){ref-type="ref"} We identified very limited evidence on self‐sampling kits and no evidence on self‐testing for HBV/HCV. Rather than indicating a lack of interest or limited applicability, this may reflect the lack of technology availability for HBV/HCV self‐testing. However, as these technologies become available in the future, self‐testing may become a potentially important approach to expand access to testing.[106](#jvh13182-bib-0106){ref-type="ref"} Transferability of the evidence and relevance of these approaches from the HIV field may contribute to this process.

Barriers to testing exist at individual, healthcare provider and institutional levels which can impede case‐finding efforts. In general, the asymptomatic course of HBV/HCV, low levels of knowledge and awareness and fear of stigma and discrimination may prevent people from seeking testing or accepting test offer.[32](#jvh13182-bib-0032){ref-type="ref"}, [58](#jvh13182-bib-0058){ref-type="ref"}, [107](#jvh13182-bib-0107){ref-type="ref"}, [108](#jvh13182-bib-0108){ref-type="ref"}, [109](#jvh13182-bib-0109){ref-type="ref"}, [110](#jvh13182-bib-0110){ref-type="ref"}, [111](#jvh13182-bib-0111){ref-type="ref"}, [112](#jvh13182-bib-0112){ref-type="ref"} For vulnerable populations, health and social problems, unstable or unstructured lives and poverty can be barriers, for PWID venous access can be an issue and for people with a migration background, culture, faith and language and their perceptions and understanding of the health care system may present barriers to testing.[29](#jvh13182-bib-0029){ref-type="ref"}, [58](#jvh13182-bib-0058){ref-type="ref"}, [109](#jvh13182-bib-0109){ref-type="ref"}, [110](#jvh13182-bib-0110){ref-type="ref"}, [111](#jvh13182-bib-0111){ref-type="ref"}, [113](#jvh13182-bib-0113){ref-type="ref"} The proximity of health care services to individuals, low awareness among health care professionals and forgetting to test are barriers that may exist at the testing provider level.[58](#jvh13182-bib-0058){ref-type="ref"}, [109](#jvh13182-bib-0109){ref-type="ref"}, [113](#jvh13182-bib-0113){ref-type="ref"} Barriers specific to health care include administrational limitations, time limitations and the GP\'s relationship with their patients.[29](#jvh13182-bib-0029){ref-type="ref"}, [32](#jvh13182-bib-0032){ref-type="ref"}, [113](#jvh13182-bib-0113){ref-type="ref"} Potential barriers specific to community include inconvenient testing facilities and lack of advocacy and promotion.[109](#jvh13182-bib-0109){ref-type="ref"}, [112](#jvh13182-bib-0112){ref-type="ref"} At an institutional level, pressures, capacity and funding shortages in primary healthcare sectors and community organizations can present barriers to testing.[109](#jvh13182-bib-0109){ref-type="ref"}, [110](#jvh13182-bib-0110){ref-type="ref"} Implementing certain testing strategies may help to alleviate many of these barriers; for example, educational initiatives, campaigns and other health promotional activities could help to raise awareness and knowledge within certain populations, the wider public and healthcare professionals. Using novel techniques such as DBS or oral sampling can bypass any issues with venous access. Demedicalizing services and bringing them out into the community could circumvent barriers which exist within healthcare settings. Implementing testing activities in a range of settings could lessen the impact of setting‐specific barriers.

The comparability of data retrieved in the systematic review was limited by the large degree of heterogeneity between studies in the outcomes measured, the specific populations targeted, recruitment and length of interventions, and whether testing initiatives were combined with health promotional activities, all of which could influence the success of the intervention. In addition, the lack of a threshold for sufficient levels of testing uptake or coverage precluded quantitative analysis. The majority of studies did not use a comparator to assess effectiveness of interventions. Furthermore, none of the studies retrieved assessed the long‐term outcomes of interventions such as the impact of testing on prevalence and incidence over time. Few studies were deemed to be of high quality and the majority had a study design which precluded formal quality assessment. For these studies, the most common quality issues noted were a lack of clarity or detail in methodology (eg data collection methods), limited description of the study population and unclear or inappropriate denominator. A significant proportion (16%) of the evidence base of the review was from included conference abstracts, that is non‐peer‐reviewed literature for which methods and results were often extremely limited and quality assessment was not possible.

In conclusion, evidence was retrieved for successful testing approaches applied in primary health care, hospital and other healthcare settings and community settings, although within most settings the evidence was fairly limited. Testing approaches targeting population groups at high risk of HBV/HCV were found to be viable in various settings, and there was evidence that other interventions such as awareness campaigns, education and the implementation of testing in the context of a national strategy may improve coverage by helping to overcome some of the barriers to testing. DBS was also associated with increased testing coverage in several different settings and other potentially effective testing strategies include contact tracing, home sampling and birth cohort testing. Further research and an understanding of local factors including the epidemiology are needed to provide policymakers with a clearer overview of which initiatives will be most successful in improving testing uptake and yielding high positivity rates. However, combining a diverse set of testing opportunities within national testing strategies may lead to higher impact in terms of both testing coverage and reduction of the undiagnosed fraction. Elimination of viral hepatitis in Europe by 2030, according to the WHO regional goal, will require diagnosing those infected and ensuring linkage to appropriate prevention, care, treatment and support services.[14](#jvh13182-bib-0014){ref-type="ref"}, [95](#jvh13182-bib-0095){ref-type="ref"} Implementation of diversified set of effective, evidence‐based testing strategies, particularly among vulnerable and hard‐to‐reach populations is a vital step in realizing this goal.
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